Mistletoe Therapy Research & Clinical Studies

Explore published research on Viscum album (European mistletoe) and its use in integrative cancer care.

LEARN MORE

About This Research Directory

  • At Freedom Integrative Cancer Care, we believe patients should have access to clear, credible information when exploring their care options. This directory brings together published research on Viscum album (European mistletoe), including studies examining its use in supportive cancer care, quality of life, safety, and specific cancer types. We’ve organized the research to make it easier to explore, with links to the original published studies so you can review the evidence directly.

    How to Use This Directory

    Each study includes a brief plain-language summary highlighting key findings and important limitations. Select “View Study on PubMed” to read the original publication and explore the research in greater detail.

Explore the Research

Browse published studies by research type, cancer type, and area of interest.

Reviews & Meta-Analyses

Explore broader reviews of the clinical evidence surrounding Viscum album, including research on survival, quality of life, safety, and its potential role alongside conventional cancer care.

  • This systematic review and meta-analysis examined controlled studies evaluating survival among cancer patients receiving Iscador, a fermented Viscum album extract. The analysis found an association between adjunctive Iscador treatment and improved survival across the studies reviewed. The authors also noted important limitations, including that none of the included studies were blinded and that outcomes varied between cancer types.

    Published: 2020
    View Study on PubMed

  • This 2020 systematic review and meta-analysis examined 26 publications evaluating mistletoe extracts and quality of life in people with cancer. Overall, the analysis reported improvements in global quality of life and several individual measures, including pain and nausea. The authors noted considerable differences between the studies and identified a high or concerning risk of bias in many of them.

    Published: 2020
    View Study on PubMed

  • This review examined preclinical and clinical research surrounding the use of mistletoe extracts in cancer care. The authors reported that evidence regarding survival remains inconsistent, while findings related to quality of life and the tolerability of conventional cancer treatments have generally been more positive. The review also highlights the need for continued scientific evaluation of mistletoe therapy.

    Published: 2020
    View Study on PubMed

  • This review explores how compounds found in Viscum album may interact with immune responses and cellular pathways involved in cancer. It examines proposed immunomodulatory mechanisms and their potential relevance to anticancer therapy, providing an overview of the biological research behind mistletoe's use in integrative oncology.

    Published: 2019
    View Study on PubMed

  • This systematic review evaluated controlled clinical studies investigating European mistletoe extracts and quality of life in people with cancer. The authors reported potential benefits for quality of life and reductions in some side effects associated with conventional treatments, while identifying fatigue as an area warranting further investigation.

    Published: 2010
    View Study on PubMed

  • This systematic review evaluated clinical evidence surrounding the efficacy and safety of mistletoe preparations used alongside conventional cancer care. The authors found evidence suggesting potential quality-of-life benefits and described supportive mistletoe therapy as generally well tolerated, while also noting limitations in the available research.

    Published: 2009
    View Study on PubMed

Breast Cancer

Explore clinical research examining mistletoe therapy in breast cancer care, including studies on quality of life, treatment-related symptoms, disease progression, and long-term outcomes.  

  • This randomized, placebo-controlled, double-blind trial followed 352 breast cancer patients receiving chemotherapy. Patients who received standardized mistletoe extract reported improvements in physical, emotional and functional well-being compared with the placebo group. The treatment was generally well tolerated, with mild local injection-site reactions reported in some patients.

    Published: 2006
    View Study on PubMed

  • This randomized pilot study evaluated mistletoe extract alongside chemotherapy in women with early-stage breast cancer. Quality-of-life measures generally favoured the mistletoe group, with statistically significant differences reported across several measures. The study was relatively small, and the authors described it as a pilot study intended to inform further research.

    Published: 2009
    View Study on PubMed

  • This five-year follow-up examined recurrence and metastasis among early-stage breast cancer patients who had participated in a randomized study of mistletoe therapy alongside chemotherapy. Six of 28 patients in the mistletoe group and eight of 29 controls experienced relapse or metastasis. The difference was not statistically significant, and the researchers concluded that additional mistletoe therapy during chemotherapy did not influence recurrence or metastasis rates within the five-year follow-up period.

    Published: 2012
    View Study on PubMed

  • This randomized, open-label pilot study evaluated a European mistletoe extract alongside chemotherapy in women with breast cancer. Patients receiving mistletoe therapy reported better results across several quality-of-life measures compared with the control group. Rates of neutropenia were similar between the groups, and the authors noted that the open-label design was an important limitation.

    Published: 2014
    View Study on PubMed

  • This large observational cohort study followed more than 1,400 patients with primary, non-metastatic breast cancer receiving conventional cancer treatment, with or without complementary mistletoe extract. The mistletoe group experienced fewer reported adverse reactions attributed to conventional therapy and improvements in several disease- and treatment-related symptoms. The researchers also reported an association with longer survival; however, as an observational rather than randomized trial, the findings cannot establish that mistletoe treatment caused the difference in survival.

    Published: 2004
    View Study on PubMed

  • These prospective matched-pair cohort studies investigated long-term Iscador therapy in breast cancer patients, examining survival, disease progression and psychosomatic self-regulation. The researchers reported favourable survival and disease-progression outcomes in some comparisons involving mistletoe treatment. The evidence included both randomized and non-randomized cohorts with relatively small matched groups, which should be considered when interpreting the results.

    Published: 2006
    View Study on PubMed

  • This prospective study followed 270 breast cancer patients receiving mistletoe therapy during adjuvant chemotherapy in routine clinical practice. Quality-of-life measures remained relatively stable during chemotherapy and improved following treatment. Because the study did not include a comparable untreated control group, the results show how patients changed over time but cannot determine how much of that change was attributable specifically to mistletoe therapy.

    Published: 2011
    View Study on PubMed

Lung Cancer

Explore published research on Viscum album in lung cancer care, including its use alongside chemotherapy, immunotherapy, and radiation, as well as studies examining survival, quality of life, and supportive care.

  • This multicentre observational study examined patients with stage IV non-small cell lung cancer (NSCLC) receiving chemotherapy, with or without additional Viscum album therapy. The researchers reported longer overall survival among patients receiving the combined treatment. Because this was an observational rather than randomized study, the results show an association and cannot establish that mistletoe therapy was responsible for the difference in survival.

    Published: 2018
    View Study on PubMed

  • This real-world study evaluated 415 patients with advanced or metastatic NSCLC receiving immune checkpoint inhibitor therapy, either alone or with additional Viscum album treatment. The combined-treatment group had longer median overall survival after adjustment for several clinical factors. The authors noted that the non-randomized observational design limits the conclusions that can be drawn and recommended prospective randomized trials.

    Published: 2024
    View Study on PubMed

  • This real-world study examined quality of life among lung cancer patients receiving radiotherapy as part of multimodal cancer treatment, including patients who also received Viscum album therapy. The research explored patient-reported outcomes including pain, nausea and other quality-of-life measures, contributing to the growing body of research on mistletoe as a supportive therapy during conventional cancer treatment.

    Published: 2023
    View Study on PubMed

  • This retrospective study evaluated the use of Helixor-M, a Viscum album extract, for pleurodesis in 52 lung cancer patients with malignant pleural effusion. Researchers assessed recurrence of pleural fluid following treatment and reported that the procedure was generally tolerable, with pain and fever among the most commonly reported treatment-related effects. The authors concluded that further research is warranted to better establish its role in managing malignant pleural effusion.

    Published: 2019
    View Study on PubMed

Pancreatic Cancer

Review clinical research on mistletoe therapy in pancreatic cancer, including studies examining survival, quality of life, and supportive care. Findings have varied across studies, including more recent randomized, placebo-controlled research that did not find a survival or quality-of-life benefit. 

  • This randomized phase III trial evaluated Viscum album extract alongside best supportive care in 220 patients with locally advanced or metastatic pancreatic cancer. The researchers reported longer median overall survival in the mistletoe group compared with the control group. The study was open-label rather than blinded, an important consideration when interpreting the findings.

    Published: 2013
    View Study on PubMed

  • Using data from the same randomized clinical trial, researchers examined quality of life and body weight in patients with advanced pancreatic cancer. Patients receiving mistletoe therapy reported better outcomes across several functional and symptom measures, including fatigue, pain, appetite loss and insomnia. These findings suggest a potential supportive-care benefit, although the study's open-label design should be considered.

    Published: 2014
    View Study on PubMed

  • This double-blind, placebo-controlled trial included 290 patients with advanced pancreatic cancer receiving standard oncological treatment and palliative care. Unlike earlier studies, researchers found no improvement in overall survival with the addition of mistletoe extract. This well-controlled study provides important newer evidence when evaluating mistletoe therapy for advanced pancreatic cancer.

    Published: 2024
    View Study on PubMed

  • A subsequent analysis of the MISTRAL trial examined quality of life, body weight, supportive-care needs and selected biomarkers. Researchers found no statistically significant differences in quality of life or body weight between patients receiving mistletoe extract and those receiving placebo. The findings add important context to earlier studies that reported quality-of-life improvements.

    Published: 2026
    View Study on PubMed

  • This retrospective analysis examined intratumoral mistletoe treatment in patients with unresectable pancreatic cancer receiving multimodal cancer care. The researchers reported that the treatment was feasible and generally well tolerated. Because patients also received chemotherapy and other treatments and there was no control group, the effect of mistletoe itself could not be determined.

    Published: 2014
    View Study on PubMed

  • This case report describes an individual with advanced pancreatic cancer who experienced long-term survival while receiving conventional treatment together with Viscum album extracts. While the case is of clinical interest, an individual case report cannot establish whether mistletoe therapy contributed to the patient's outcome.

    Published: 2019
    View Study on PubMed

Colorectal Cancer

Explore research on Viscum album in colorectal cancer care, including studies examining treatment-related symptoms, fatigue, immune function, disease-free survival, and advanced disease. Findings have varied, and some studies have not demonstrated an objective antitumour response. 

  • This multicentre observational cohort study followed 804 patients with stage I–III colorectal cancer who had undergone surgery and received conventional cancer treatment or aftercare, with or without additional Iscador mistletoe therapy. Patients receiving mistletoe experienced fewer treatment-related adverse reactions and persistent symptoms. Researchers also reported an association with longer disease-free survival; however, because this was an observational rather than randomized trial, the findings cannot establish that mistletoe treatment caused the difference.

    Published: 2009
    View Study on PubMed

  • This study examined 324 patients with non-metastatic colorectal cancer receiving chemotherapy or chemoradiotherapy, including 181 who also received supportive mistletoe therapy. Researchers reported substantially less cancer-related fatigue in the mistletoe group by the end of the treatment period. Because treatment allocation was not randomized, other differences between the patient groups may have contributed to the results.

    Published: 2014
    View Study on PubMed

  • This randomized clinical trial investigated whether perioperative mistletoe treatment could influence the temporary suppression of natural killer (NK) cell activity that can occur following major surgery. Colorectal cancer patients undergoing tumour resection received either a mistletoe infusion or no additional therapy. The researchers reported that mistletoe treatment reduced the postoperative suppression of NK cell activity, although the study was designed to assess immune function rather than cancer recurrence or survival.

    Published: 2007
    View Study on PubMed

  • This clinical study evaluated mistletoe extract in 25 patients with metastatic colorectal cancer whose disease had progressed despite 5-fluorouracil and leucovorin-based chemotherapy. No objective tumour responses were observed, although stable disease was reported temporarily in some patients and 40% reported symptomatic relief. The researchers concluded that mistletoe extract did not demonstrate objective antitumour activity in this group of patients.

    Published: 2004
    View Study on PubMed

  • This controlled study examined 70 patients undergoing surgery for cancers of the digestive tract, including 36 patients with colorectal cancer. Patients receiving Viscum album extract before and after surgery showed differences in several immune-system measures compared with controls, including natural killer cells and T and B cells. Because the study included several different digestive cancers and focused primarily on immune responses, it does not establish an effect on colorectal cancer outcomes.

    Published: 2005
    View Study on PubMed

Gynecological Cancers

Explore published research involving cervical, ovarian, and other gynecological cancers, including studies examining long-term outcomes, supportive mistletoe therapy, and its use alongside targeted cancer treatments. Much of the available evidence is observational, older, or based on small patient populations. 

  • This prospective research followed cervical cancer patients in three controlled cohort studies to examine survival, tumour progression and psychosomatic self-regulation during long-term Iscador therapy. The research included both randomized matched-pair and non-randomized comparisons. Some favourable outcomes were reported, but the relatively small randomized group and observational components of the research limit the conclusions that can be drawn.

    Published: 2007
    View Study on PubMed

  • This comparative clinical study examined 25 women with ovarian cancer who received postoperative Iscador treatment, most of whom had advanced stage III or IV disease. Researchers reported longer average survival compared with a separate group of 22 patients receiving another treatment. The study was conducted decades ago with a small, non-randomized patient population, so its findings should be interpreted cautiously in the context of current ovarian cancer care.

    Published: 1979
    View Study on PubMed

  • This case report describes a woman with stage IV epithelial ovarian cancer who underwent extensive surgery, chemotherapy, high-dose chemotherapy and stem cell transplantation while also receiving long-term Viscum album extract. She remained tumour-free during long-term follow-up. Because multiple cancer treatments were used and this report describes a single patient, it cannot establish what role, if any, mistletoe therapy played in the outcome.

    Published: 2018
    View Study on PubMed

  • This real-world observational study evaluated the safety of combining targeted cancer therapies with Helixor Viscum album in patients with breast and gynecological cancers. Researchers compared adverse drug reactions among patients receiving targeted therapy alone with those receiving additional mistletoe treatment. The study contributes useful safety information about mistletoe alongside newer targeted therapies, although its observational design does not establish treatment efficacy.

    Published: 2023
    View Study on PubMed

Quality of Life

Explore research examining how mistletoe therapy may relate to fatigue, sleep, appetite, treatment-related symptoms, emotional well-being, and overall quality of life when used as part of supportive cancer care. 

  • This prospective cohort study followed 25 patients with different types of cancer receiving mistletoe therapy alongside conventional care. After three months, researchers reported improvements in several quality-of-life measures, while patient interviews described increased vitality, autonomy, and ability to cope with their illness. Because the study was small and did not include a control group, it cannot determine whether mistletoe therapy itself caused these improvements.

    Published: 2012
    View Study on PubMed

  • This systematic review examined qualitative research exploring cancer patients' experiences with mistletoe therapy. Patients described perceived improvements in physical, emotional, and psychosocial well-being, as well as reductions in some chemotherapy-related side effects. The authors emphasized that these were patient-reported experiences and that improvements could not necessarily be attributed specifically to mistletoe therapy.

    Published: 2016
    View Study on PubMed

  • This systematic review evaluated 28 publications involving 2,639 cancer patients, with 17 publications reporting quality-of-life outcomes. While some studies reported improvements, the authors found that studies with stronger methodology tended to show smaller or no quality-of-life effects. They concluded that the available evidence did not provide sufficient support for prescribing mistletoe specifically to improve quality of life or reduce treatment-related side effects.

    Published: 2019
    View Study on PubMed

Safety & Tolerability

Explore published research examining the safety and tolerability of Viscum album therapy, including reported adverse reactions and its use alongside conventional cancer treatments. Larger observational studies have generally reported mild-to-moderate reactions, while rare serious allergic reactions have also been documented.

  • This retrospective cohort study compared adverse reactions among 1,361 cancer patients who began Viscum album therapy at either the recommended low initial dose or a higher initial dose. Adverse reactions were more frequent among patients starting at the higher dose, although nearly all were mild to moderate and no serious adverse drug reactions were reported. The findings highlight the relationship between starting dose and treatment reactions. 

    Published: 2017
    View Study on PubMed

  • This multicentre observational study examined adverse drug reactions associated with subcutaneous mistletoe therapy in cancer patients. Reported reactions were generally mild to moderate, with local injection-site reactions and temporary systemic symptoms among the most common. Serious treatment-related reactions were uncommon in the patient population studied.

    Published: 2014
    View Study on PubMed

  • This observational study evaluated the safety of intravenous Viscum album preparations in 475 cancer patients. Twenty-two patients experienced adverse drug reactions, all of which were classified as mild or moderate, and no serious adverse reactions were reported. The study provides safety information about intravenous mistletoe administration, a route that has been studied less extensively than subcutaneous treatment. 

    Published: 2014
    View Study on PubMed

  • This observational study examined cancer patients receiving monoclonal antibody therapy with or without additional Viscum album treatment. Researchers found no evidence that adding mistletoe increased the overall rate of adverse events associated with antibody treatment. Because the study was observational, additional controlled research is needed to further evaluate safety across specific cancer therapies.

    Published: 2018
    View Study on PubMed

  • This real-world study evaluated the safety of Viscum album used alongside targeted therapies in patients with breast and gynecological cancers. Researchers examined adverse drug reactions and found that adding mistletoe therapy was not associated with an increased overall rate of treatment-related adverse reactions in the study population.

    Published: 2018 
    View Study on PubMed

Have Questions About Mistletoe Therapy?

Research is only one part of understanding whether an integrative therapy may be appropriate for you. Our team can help you explore mistletoe therapy within the context of your diagnosis, current treatment plan, and overall care.

BOOK A CONSULTATION